home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Egr-1: A New Ischemia Drug Target

  December, 3 2000 0:49
your information resource in human molecular genetics
When a blood vessel becomes blocked, the tissue that it serves experiences ischemia—a state of low oxygen supply—that slowly kills the tissue. If and when blood flow returns (reperfusion), it can often cause even greater damage to the tissue. This type of ischemia/reperfusion (IR) injury occurs in heart attacks, and understanding the mechanisms involved in IR could lead to the development of new drugs to save damaged tissue and treat heart attack.

Using a mouse lung model of IR, David Stern and colleagues at Columbia University, have now discovered that one molecule unifies many of the pathways that lead to IR tissue damage (Nature Medicine, Vol. 6, Issue 12, 01 Dec 2000). The scientists stopped blood flow to the lungs for 60 minutes and then reperfused them for 3 hours. They saw that levels of the Early growth response (Egr-1) gene were elevated substantially during IR. They also demonstrated that Egr-1 is the common link between the diverse pathways that cause tissue injury, such as the stimulation of chemokines, adhesion receptor molecules, procoagulants, and permeability-related genes. Deleting the Egr-1 gene decreased tissue injury and enhanced animal survival and organ function.

These studies show that Egr-1 plays a central role in ischemic tissue damage, and suggest that Egr-1 may be a good drug target for the treatment of ischemic conditions.


Dr David M Stern
Department of Surgery
P&S 17-401
College of Physicians & Surgeons of Columbia University
630 West 168th Street
New York, NY, 10032
Tel: +1 212 305 1615
Fax: +1 212 305 5337
Email: dms9@columbia.edu

(C) Nature Medicine press release

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.